ERBB2 and breast cancer: Over 70% of breast cancers show activation of the PI3K pathway through mechanisms such as HER2 amplification, deletion of the tumor suppressor PTEN, or oncogenic mutations in PIK3CA (Zhao and Vogt, 2008).